Can I read Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial on EtoBox?

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial by Atsuo Takashima; Kohei Shitara; Kazumasa Fujitani; Keisuke Koeda; Hiroki Hara; Norisuke Nakayama; Shuichi Hironaka; Kazuhiro Nishikawa; Yutaka Kimura; Kenji Amagai; Hirofumi Fujii; Kei Muro; Taito Esaki; Yasuhiro Choda; Toshimi Takano; Keisho Chin; Atsushi Sato; Masahiro Goto; Norimasa Fukushima; Takuo Hara; Nozomu Machida; Manabu Ohta; Narikazu Boku; Masashi Shimura; Satoshi Morita; Wasaburo Koizumi is a Medicine article available to read on EtoBox.

What is Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial about?

Background In the ABSOLUTE trial, weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) showed non-inferiority to weekly solvent-based paclitaxel (w-sb-PTX) for overall survival (OS). Thus, w-nab-PTX might be an option for secondline chemotherapy in advanced gastric cancer (AGC). However, predictive factors for efficacies of these agents have not been evaluated. Methods Patients previously enrolled in the ABSOLUTE trial were divided into apparent peritoneal metastasis group (PM group) and no apparent peritoneal metastasis group (no PM group) based on baseline imaging evaluated by RECIST ver. 1.1 criteria and amount of ascites. OS, progression-free survival, and overall response rate were compared between two arms in each group. Results This study included 240 and 243 patients in the w-nab-PTX and w-sb-PTX arms, respectively. In the PM group, the w-nab-PTX arm (n = 88) had longer OS than the w-sb-PTX arm (n = 103), and median survival time (MST) of 9.9 and 8.7 months [hazard ratio (HR) 0.63; 95% CI 0.45-0.88; P = 0.0060], respectively. In the no PM group, the w-nab-PTX arm (n = 140) had shorter OS than the w-sb-PTX arm (n = 152), and MST of 11.6 and 15.7 months (HR 1.40; 95% CI 1

Who reads Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial?

Author

Atsuo Takashima; Kohei Shitara; Kazumasa Fujitani; Keisuke Koeda; Hiroki Hara; Norisuke Nakayama; Shuichi Hironaka; Kazuhiro Nishikawa; Yutaka Kimura; Kenji Amagai; Hirofumi Fujii; Kei Muro; Taito Esaki; Yasuhiro Choda; Toshimi Takano; Keisho Chin; Atsushi Sato; Masahiro Goto; Norimasa Fukushima; Takuo Hara; Nozomu Machida; Manabu Ohta; Narikazu Boku; Masashi Shimura; Satoshi Morita; Wasaburo Koizumi

Publisher

Springer Science and Business Media LLC

Published

2018

Language

EN

Field

Medicine (Health Sciences)